Riccardo Paggi
1 Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Francesca Mariotti
1 Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Jessica Mencarini
1 Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy; 2 Infectious and Tropical Diseases Unit, Careggi University Hospital, Florence, Italy.
Silvia Bresci
2 Infectious and Tropical Diseases Unit, Careggi University Hospital, Florence, Italy.
Irene Capolmi
2 Infectious and Tropical Diseases Unit, Careggi University Hospital, Florence, Italy.
Filippo Bartalesi
1 Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy; 2 Infectious and Tropical Diseases Unit, Careggi University Hospital, Florence, Italy.
Beatrice Borchi
2 Infectious and Tropical Diseases Unit, Careggi University Hospital, Florence, Italy.
Luca Nassi
3 Hematology Unit, Azienda Ospedaliera Universitaria Careggi, University of Florence, Florence, Italy.
Alessandro Maria Vannucchi
4 Center for Innovation and Research in Myeloproliferative Neoplasms, Hematology Unit, Azienda Ospedaliera Universitaria Careggi, University of Florence, Florence, Italy.
Alessandro Bartoloni
1 Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy; 2 Infectious and Tropical Diseases Unit, Careggi University Hospital, Florence, Italy.
Keywords
Waldenström’s Macroglobulinemia, Invasive Aspergillosis, Orbital Lymphoma, Bruton Kinase Inhibitors, Lacrimal Glands Lymphoma×
Abstract
The use of specific inhibitory drugs of intracellular signaling pathways (such as Bruton-Kinase inhibitors) for the treatment of Waldenström's macroglobulinemia (WM) is a recognized risk factor for Aspergillus spp. infections. The overlapping clinical manifestations of the two diseases may require the involvement of different medical specialties.